Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial

D Molina-Morant, M L Fernández, P Bosch-Nicolau, E Sulleiro, M Bangher, F Salvador, A Sanchez-Montalva, A L P Ribeiro, A M B de Paula, S Eloi, R Correa-Oliveira, J C Villar, S Sosa-Estani, I Molina, D Molina-Morant, M L Fernández, P Bosch-Nicolau, E Sulleiro, M Bangher, F Salvador, A Sanchez-Montalva, A L P Ribeiro, A M B de Paula, S Eloi, R Correa-Oliveira, J C Villar, S Sosa-Estani, I Molina

Abstract

Background: Chagas disease (CD) continues to be a neglected infectious disease with one of the largest burdens globally. Despite the modest cure rates in adult chronic patients and its safety profile, benznidazole (BNZ) is still the drug of choice. Its current recommended dose is based on nonrandomized studies, and efficacy and safety of the optimal dose of BNZ have been scarcely analyzed in clinical trials.

Methods/design: MULTIBENZ is a phase II, randomized, noninferiority, double-blind, multicenter international clinical trial. A total of 240 patients with Trypanosoma CD in the chronic phase will be recruited in four different countries (Argentina, Brazil, Colombia, and Spain). Patients will be randomized to receive BNZ 150 mg/day for 60 days, 400 mg/day for 15 days, or 300 mg/day for 60 days (comparator arm). The primary outcome is the efficacy of three different BNZ therapeutic schemes in terms of dose and duration. Efficacy will be assessed according to the proportion of patients with sustained parasitic load suppression in peripheral blood measured by polymerase chain reaction. The secondary outcomes are related to pharmacokinetics and drug tolerability. The follow-up will be 12 months from randomization to end of study participation. Recruitment was started in April 2018.

Conclusion: This is a clinical trial conducted for the assessment of different dose schemes of BNZ compared with the standard treatment regimen for the treatment of CD in the chronic phase. MULTIBENZ may help to clarify which is the most adequate BNZ regimen in terms of efficacy and safety, predicated on sustained parasitic load suppression in peripheral blood.

Trial registration: ClinicalTrials.gov, NCT03191162. Registered on 19 June 2017.

Keywords: Benznidazole; Chagas disease; Clinical trial; Multicenter study; Therapeutic.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Clinical trial design. BNZ Benznidazole, BV Baseline visit, EoF End of follow-up, FV Follow-up visit, SV Screening visit, TV Treatment visit

References

    1. WHO. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015;90(6):33–43..
    1. Molina I, Salvador F, Sánchez-Montalvá A. Update Chagas disease [in Spanish] Enferm Infecc Microbiol Clin. 2016;34(2):132–138. doi: 10.1016/j.eimc.2015.12.008.
    1. Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94. doi: 10.1016/S0140-6736(17)31612-4.
    1. Noya BA, Pérez-Chacón G, Díaz-Bello Z, Dickson S, Muñoz-Calderón A, Hernández C, et al. Description of an oral Chagas disease outbreak in Venezuela, including a vertically transmitted case. Mem Inst Oswaldo Cruz. 2017;112(8):569–571. doi: 10.1590/0074-02760170009.
    1. Sánchez-Montalvá A, Salvador F, Rodríguez-Palomares J, Sulleiro E, Sao-Avilés A, Roure S, et al. Chagas cardiomyopathy: usefulness of EKG and echocardiogram in a non-endemic country. PLoS One. 2016;11(6):e0157597. doi: 10.1371/journal.pone.0157597.
    1. Machado FS, Jelicks LA, Kirchhoff LV, Shirani J, Nagajyothi F, Mukherjee S, et al. Chagas heart disease: report on recent developments. Cardiol Rev. 2012;20(2):53–65. doi: 10.1097/CRD.0b013e31823efde2.
    1. Sales Junior PA, Molina I, Fonseca Murta SM, Sánchez-Montalvá A, Salvador F, Corrêa-Oliveira R, et al. Experimental and clinical treatment of Chagas disease: a review. Am J Trop Med Hyg. 2017;97(5):1289–1303. doi: 10.4269/ajtmh.16-0761.
    1. Bern C. Antitrypanosomal therapy for chronic Chagas’ disease. N Engl J Med. 2011;364(26):2527–2534. doi: 10.1056/NEJMct1014204.
    1. Molina I, Salvador F, Sánchez-Montalvá A, Treviño B, Serre N, Sao Avilés A. Toxic profile of benznidazole in patients with chronic Chagas disease: risk factors and comparison of the product from two different manufacturers. Antimicrob Agents Chemother. 2015;59(10):6125–6131. doi: 10.1128/AAC.04660-14.
    1. Hasslocher-Moreno AM, do Brasil PEAA, de Sousa AS, Xavier SS, Chambela MC, Sperandio da Silva GM. Safety of benznidazole use in the treatment of chronic Chagas’ disease. J Antimicrob Chemother. 2012;67(5):1261–1266. doi: 10.1093/jac/dks027.
    1. Salvador F, Sánchez-Montalvá A, Martínez-Gallo M, Sala-Cunill A, Viñas L, García-Prat M, et al. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Clin Infect Dis. 2015;61(11):1688–1694.
    1. Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz. 2011;106(6):641–645. doi: 10.1590/S0074-02762011000600001.
    1. Sguassero Y, Roberts KN, Harvey GB, Comandé D, Ciapponi A, Cuesta CB, et al. Course of serological tests in treated subjects with chronic Trypanosoma cruzi infection: a systematic review and meta-analysis of individual participant data. Int J Infect Dis. 2018;73:93–101. doi: 10.1016/j.ijid.2018.05.019.
    1. Pan American Health Organization (PAHO) Guidelines for the diagnosis and treatment of Chagas disease. Washington, DC: PAHO; 2018.
    1. Fabbro DL, Danesi E, Olivera V, Codebó MO, Denner S, Heredia C, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis. 2014;8(11):e3312. doi: 10.1371/journal.pntd.0003312.
    1. Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009;64:1139–1147. doi: 10.1093/jac/dkp357.
    1. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373:1295–1306. doi: 10.1056/NEJMoa1507574.
    1. Richle RW, Raaflaub J. Difference of effective antitrypanosomal dosages of Benznidazole in mice and man. Chemotherapeutic and pharmacokinetic results. Acta Trop. 1980;37(3):257–261.
    1. Altcheh J, Moscatelli G, Mastrantonio G, Moroni S, Giglio N, Marson ME, et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis. 2014;8(5):e2907. doi: 10.1371/journal.pntd.0002907.
    1. Soy D, Aldasoro E, Guerrero L, Posada E, Serret N, Mejía T, et al. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother. 2015;59(6):3342–3349. doi: 10.1128/AAC.05018-14.
    1. Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung. 1979;29:1611–1614.
    1. Raaflaub J. Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung. 1980;30:2192–2194.
    1. Moraes CB, Giardini MA, Kim H, Franco CH, Araujo-Junior AM, Schenkman S, et al. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep. 2014;4:4703. doi: 10.1038/srep04703.
    1. Morillo CA, Waskin H, Sosa-Estani S, Del Carmen Bangher M, Cuneo C, Milesi R. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. Cruzi carriers: the STOP-CHAGAS trial. J Am Coll Cardiol. 2017;69(8):939–947. doi: 10.1016/j.jacc.2016.12.023.
    1. Pinazo MJ, Guerrero L, Posada E, Rodríguez E, Soy D, Gascon J. Benznidazole- related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic Chagas disease. Antimicrob Agents Chemother. 2013;57(1):390–395. doi: 10.1128/AAC.01401-12.
    1. Francisco AF, Lewis MD, Jayawardhana S, Taylor MC, Chatelain E, Kelly JM. Limited ability of Posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging. Antimicrob Agents Chemother. 2015;59(8):4653–4661. doi: 10.1128/AAC.00520-15.
    1. BENDITA (Benznidazole New Doses Improved Treatment and Associations) study. identifier: NCT03378661. . Accessed 11 Mar 2020.
    1. Álvarez MG, Hernández Y, Bertocchi G, Fernández M, Lococo B, Ramírez JC, et al. New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: a pilot short-term follow-up study with adult patients. Antimicrob Agents Chemother. 2015;60(2):833–837. doi: 10.1128/AAC.00745-15.
    1. Alvarez MG, Vigliano C, Lococo B, Petti M, Bertocchi G, Viotti R. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease. Trans R Soc Trop Med Hyg. 2012;106:636–638. doi: 10.1016/j.trstmh.2012.07.010.
    1. Duffy T, Cura CI, Ramirez JC, Abate T, Cayo NM, Parrado R, Bello ZD, Velazquez E, Muñoz-Calderon A, Juiz NA, Basile J, Garcia L, Riarte A, Nasser JR, Ocampo SB, Yadon ZE, Torrico F, de Noya BA, Ribeiro I, Schijman AG. Analytical performance of a multiplex Real-Time PCR assay using TaqMan probes for quantification of Trypanosoma cruzi satellite DNA in blood samples. PLoS Negl Trop Dis. 2013;7(1):e2000.
    1. Gomes ML, Galvao LM, Macedo AM, et al. CD diagnosis: comparative analysis of parasitologic, molecular, and serologic methods. Am J Trop Med Hyg. 1999;60:205–210. doi: 10.4269/ajtmh.1999.60.205.
    1. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther. 2009;7:157–163. doi: 10.1586/14787210.7.2.157.
    1. Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis) Hum Exp Toxicol. 2006;25:471–479. doi: 10.1191/0960327106het653oa.
    1. Favaretto AL, Antunes-Rodrigues J, Vieira CL, Lamano-Carvalho TL. Pituitary-testicular axis in benznidazole-treated rats. Braz J Med Biol Res. 1990;23(8):719–722.
    1. Vieira CL, Lamano-Carvalho TL, Favaretto AL, Valença MM, Antunes-Rodrigues J, Barreira AA. Testes alterations in pubertal benznidazole-treated rats. Braz J Med Biol Res. 1989;22(6):695–698.
    1. Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. PLoS Negl Trop Dis. 2009;3(7):e488. doi: 10.1371/journal.pntd.0000488.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅